Microbiome-Based Therapies are Poised to Launch Within the Next Decade How will emerging microbiome-based therapies impact disease markets, especially in gastrointestinal diseases? Key Findings: Research on the human...
In DRG Blog/ October, 2018 The Current Regulatory Environment for Microbiome-Based Therapies: Insights from the FDA's Workshop on Live Bacterial Products Microbiome-based therapies, which aim to modify the bacterial ecosystem that colonizes the human body, have been a hot area of research for the...
In DRG Blog/ September, 2018 IBS Awareness Month: Sizing Unmet Needs in the IBS-C Market Irritable bowel syndrome (IBS) is a disease you may already have heard of, but with April designated as IBS awareness month, it is worth revisiting...
In DRG Blog, Drug Watch/ April, 2018 Changing Clinical Guidelines Complicate Trials for COPD The rapid evolution of healthcare presents many challenges to drug developers; as many lucrative disease markets become mature, competing against a...
In DRG Blog, Drug Watch/ December, 2017 ERS 2017: Unanswered Questions in COPD At this year’s ERS conference, ICS therapies in COPD were a hot topic, along with changes to the GOLD international guidelines. Last week...
In DRG Blog, Drug Watch/ September, 2017 Pokemon Go: Can Games Improve Your Health? I admit that in the last week, I have gotten completely addicted to Pokémon Go. I’m just the right age for it; at almost 30, I remember playing...
In DRG Blog, Drug Watch, Digital Innovation/ July, 2016 Commercializing the Microbiome: No Guts, No Glory In the first blog post of this two-part series, we introduced the human microbiome, the increasing amount of research focused on understanding its...
In DRG Blog, Drug Watch, Digital Innovation/ July, 2016 The Human Microbiome: The Potential of the Other 99% Advances in sequencing and deciphering of genomes have given rise to a field of research that may just be two orders of magnitude more complex, the...
In DRG Blog, Drug Watch, Digital Innovation/ July, 2016 A competition case study: Nucala versus the world Patients with severe persistent asthma have an unfortunately small number of treatment options, and all of them come with significant drawbacks...
In DRG Blog, Drug Watch, Digital Innovation/ January, 2016 Bremelanotide may offer steep competition to Abbyi as soon as 2018 Abbyi, the first drug approved to enhance women’s libido, was launched in September to both accolades and objections, but in the subsequent...
In DRG Blog, Drug Watch, Digital Innovation/ December, 2015 
